Marksans Pharma Shares Skyrocket 9% on USFDA Approval 

Shares of Marksans Pharma Ltd skyrocketed 9% on 1 April after the firm announced that its Benzonatate Capsules had received approval from the US Food and Drug Administration (USFDA).

The firm announced that it had acquired final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for the capsules in 100mg and 200mg dosages.

The medication is bioequivalent and medically equivalent to Pfizer Inc’s reference listed medicine Tessalon Capsules, 100mg and 200mg, according to the manufacturer.

Benzonatate is a non-narcotic antitussive that numbs stretch receptors in the respiratory tract, lowering the cough reflex and alleviating chronic cough, bronchitis, pneumonia, and other lung infections, according to Marksans Pharma.

In November of last year, Marksans Pharma’s wholly-owned subsidiary got final FDA approval for the over-the-counter Loperamide Hydrochloride Tablets USP, 2mg.

According to the firm, Loperamide Hydrochloride tablet is an anti-diarrheal drug used to treat acute and chronic diarrhoea symptoms.

At 3:30 pm, the shares of Marksans Pharma closed 6.01% higher at Rs 166.32 on NSE.

Discover the next big investment! Tradz by EquityPandits’ IPO screener helps you identify promising initial public offerings. Download Tradz by EquityPandit and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!

The post Marksans Pharma Shares Skyrocket 9% on USFDA Approval  appeared first on Equitypandit.